Savara Inc
NASDAQ:SVRA
Savara Inc
Total Assets
Savara Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Total Assets
$212.9m
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Assets
$135.2B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Assets
$59B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Assets
$91.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Assets
$22.5B
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Assets
$37.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
21%
|
CAGR 10-Years
26%
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Total Assets?
Total Assets
212.9m
USD
Based on the financial report for Dec 31, 2024, Savara Inc's Total Assets amounts to 212.9m USD.
What is Savara Inc's Total Assets growth rate?
Total Assets CAGR 10Y
12%
Over the last year, the Total Assets growth was 20%. The average annual Total Assets growth rates for Savara Inc have been 6% over the past three years , 9% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet